Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis

• Published in: Medical principles and practice Vol. 32; no. 3; pp. 178 - 191
• Main Authors: Parida, Girish Kumar, Panda, Raj Abhisek, Bishnoi, Komal, Agrawal, Kanhaiyalal
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.10.2023
• Subjects: Actinium - therapeutic use; Antigens; Cancer therapies; Dipeptides - adverse effects; Humans; Ligands; Male; Medical prognosis; Meta-analysis; Metastasis; Patients; Prostate; Prostate cancer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - radiotherapy; Retrospective Studies; Software; Statistical analysis; Systematic Review; Toxicity; Treatment Outcome; Metastatic castration-resistant prostate cancer; Metanalysis; Actinium-225 prostate-specific membrane antigen radioligand therapy

Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to the beta-emitters such as Lutetium...